Simple exploration of 170161-27-0

170161-27-0, As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The dibromide was added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (39.1 mg, 78.0 mumol), KI (12.9 mg, 78.0 mumol) and K2CO3 (10.8 mg, 78.0 mumol) in CH3CN (2.50 mL) under N2 and stirred for 24 h at room temperature. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Boc-protected amine intermediate (130 mg). A solution of the intermediate was added to bis(pyridin-2-ylmethyl)amine (12.0 mg, 60.0 mumol), KI (9.96 mg, 60.0 mumol) and K2CO3 (8.30 mg, 60.0 mumol) in CH3CN (3.00 mL) under N2 and stirred at 80 C for 24 h. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc. The organic layer was washed with water and brine, dried with MgSO4 and concentrated in vacuo to obtain the corresponding tri-N-Boc-protected amine intermediate. The intermediate was then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compound 16.

170161-27-0, As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Analyzing the synthesis route of 170161-27-0

170161-27-0, 170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

A mixture of 4-ethynylbenzaldehyde (65 mg, 500 mol) and triBoc-cyclam (250 mg, 500mol) in dichloromethane (4 mL) was stirred at ambient temperature for 2 h, and then sodiumtriacetoxyborohydride (318 mg, 1.5 mmol) was added. The mixture was stirred at ambient temperatureovernight. The reaction was quenched with aqueous NaHCO3, the layers were separated and theaqueous layer was extracted with dichloromethane. The combined organic layers were dried overanhydrous sodium sulfate and evaporated, and the crude residue was purified by Combi-Flash (silica gel;ethyl acetate in hexanes) to give p-RPS-546 (185 mg 60%) as a white solid.

170161-27-0, 170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Article; Amor-Coarasa, Alejandro; Kelly, James M.; Singh, Pradeep K.; Ponnala, Shashikanth; Nikolopoulou, Anastasia; Williams, Clarence; Vedvyas, Yogindra; Jin, Moonsoo M.; David Warren; Babich, John W.; Molecules; vol. 24; 8; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Downstream synthetic route of 17217-57-1

17217-57-1, The synthetic route of 17217-57-1 has been constantly updated, and we look forward to future research findings.

17217-57-1, 4,4′-Dimethoxy-2,2′-bipyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Heteroleptic iridium 4xy were synthesized in a two-step procedure[42,43]. In the first step, chloro-bridged dimer was synthesized by charging a two-necked reaction flask with magnetic stir bar, iridium(III) chloride (1 equiv), ligand (2.26 equiv), and a 2:1 v:v mixture of 2-methoxyethanol/water. The mixture was degased with Ar (via Ar bubbling) and heated under reflux at 120 ¡ãC with constant stirring overnight. The reaction mixture cooled to room temperature and filtered. The precipitate was washed with water (3×10 mL), dried in air and taken onto the second step without further purification unless noted. In the second step, the chloro bridging dimer (1 equiv), bipyridyl ligand (2.2 equiv) and ethylene glycol were placed in a two-necked flask and then flushed with Ar. The mixture was heated at 150 ¡ãC for 15 h and then cooled. The cooled reaction mixture was washed hexane (3 10 mL) and mixture was heated to 85 ¡ãC for 5 min to remove residual hexane. Aqueous ammonium hexafluorophosphate (sat. solution) was added to the reaction mixture causing the iridium-PF6 salt to precipitate,which was filtered, dried and recrystallized (acetone/ether).

17217-57-1, The synthetic route of 17217-57-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Singh, Anuradha; Teegardin, Kip; Kelly, Megan; Prasad, Kariate S.; Krishnan, Sadagopan; Weaver, Jimmie D.; Journal of Organometallic Chemistry; vol. 776; (2015); p. 51 – 59;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Some tips on 29176-55-4

29176-55-4 2,9-Dichloro-1,10-phenanthroline 355196, acatalyst-ligand compound, is more and more widely used in various.

29176-55-4, 2,9-Dichloro-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a 100 mL flask was added 1245 mg (5.0 mmol) of 2,9-dichloro-phenanthroline,2160 mg (20.0 mmol) of N-allylimidazole,1500 mg (10.0 mmol) of sodium iodide (NaI)40 mL of toluene,In the 110 ~ 120 oil bath,The reaction was stirred for 96 hours.The resulting precipitate is filtered,Washed with toluene (2 x 15 mL)Ether wash (2 x 15 mL),With hot water to dissolve,Filtered and added dropwise to an aqueous solution of 3260 mg (20.0 mmol) of ammonium hexafluorophosphate (NH4PF6)The precipitated solid was dried to give the off-white powder as the ligand precursor product S1,Yield: 1026 mg (30%)., 29176-55-4

29176-55-4 2,9-Dichloro-1,10-phenanthroline 355196, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; Sinopec Corporation; Sinopec Corporation Shanghai Petrochemical Institute; Liu Bo; Jin Zhaosheng; Li Yanan; Lv Jiangang; Sun Lanping; Huang Zujuan; (19 pag.)CN105085553; (2017); B;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Analyzing the synthesis route of 131833-93-7

131833-93-7, 131833-93-7 (4S,4’S)-2,2′-(Propane-2,2-diyl)bis(4-(tert-butyl)-4,5-dihydrooxazole) 688208, acatalyst-ligand compound, is more and more widely used in various.

131833-93-7, (4S,4’S)-2,2′-(Propane-2,2-diyl)bis(4-(tert-butyl)-4,5-dihydrooxazole) is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A 5 L round bottom flask was charged with copper(I) trifluoromethanesulfonate benzene complex (39.0 g, 0.0775 mol) under a nitrogen atmosphere. The flask was charged with degassed MTBE (0.775 L) and cooled to 15 C. A solution of bisoxazoline ligand (49.7 g, 0.163 mol) in degassed MTBE (2.33 L) was added via cannula. The resulting suspension was stirred at 15-25 C. for 1 h and then allowed to stand for 30 min. The supernatant was filtered through an in-line filter to afford a deep green solution of catalyst.

131833-93-7, 131833-93-7 (4S,4’S)-2,2′-(Propane-2,2-diyl)bis(4-(tert-butyl)-4,5-dihydrooxazole) 688208, acatalyst-ligand compound, is more and more widely used in various.

Reference£º
Patent; Dube, Daniel; Gallant, Michel; Lacombe, Patrick; US2007/99951; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Downstream synthetic route of 137076-54-1

The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

(1)L-glutamic acid dibenzyl ester hydrochloride (86.9 mg),Tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate(114 mg), DMF (2 mL) and DIEA (100 muL)HBTU (83 mg) was added, and the mixture was stirred at room temperature for 30 minutes. The solvent was distilled off under reduced pressure,Ethyl acetate (5 mL) and saturated aqueous sodium chloride solution (3 mL) were added to the residue.The organic layer was separated and the aqueous layer was extracted 5 times with ethyl acetate (5 mL).The combined organic layer was dried over anhydrous magnesium sulfate,Purification by silica gel column chromatography (ethyl acetate)(H1) (96 mg)., 137076-54-1

The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; FUJIFILM Corporation; Fujifilm RI Pharma Co., Ltd.; Hirofumi, Fukunaga; Do En, Hiroyuki; Hino, Akihiro; Oshikiri, Shinobu; Chou, Rumpf; (131 pag.)JP2016/183151; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Analyzing the synthesis route of 10534-59-5

10534-59-5, As the paragraph descriping shows that 10534-59-5 is playing an increasingly important role.

10534-59-5, Tetrabutylammonium acetate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The solution of a receptor (~10-3 M) was titrated in NMR tube with the 0.1-0.3 M solution of arespective TBA salt. The solution of the salt contained a certain amount of the receptor to keep receptorconcentration constant during titration experiments. It was important to choose such volumes ofaliquots so that most of the data points could occur in close proximity of the inflection point of therespective titration curve; 11 to 23 data points were recorded. Such procedure allows for more precisecalculation of binding constants. A nonlinear curve fitting for the 1:1 binding model was carried outwith the HypNMR2008 Software [26-28] (Version 4.0.71) and allows the determination of the globalassociation constant. The details are given in ESI Figures S27-S65 and Tables S1-S38.

10534-59-5, As the paragraph descriping shows that 10534-59-5 is playing an increasingly important role.

Reference£º
Article; Tyszka-Gumkowska, Agata; Pikus, Grzegorz; Jurczak, Janusz; Molecules; vol. 24; 14; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Downstream synthetic route of 137076-54-1

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

Example 2 (S)-2,2′-bis[bis(3,5-dimethylphenyl)phosphino]-1,1′-binaphthyl Under an argon atmosphere, to a solution (5 ML) of [1,2-bis(diphenylphosphino)-ethane]dichloronickel (42 mg, 0.1 equivalent), (S)-2,2′-bis(trifluoromethanesulfonyloxy)-1,1′-binaphthyl (399 mg, 0.73 MmoL) synthesised in Reference Example 1 and 1,4-diazabicyclo[2,2,2]octane (489 mg, 6.0 equivalents) in DMF was added at room temperature a bis(3,5-dimethylphenyl)phosphine-borane complex (428 mg, 2.3 equivalents) synthesised in Example 1.. The mixture was stirred at room temperature for 30 min. and then at 110C for 96 hrs. DMF was evaporated under reduced pressure and methanol was added to the residue to give the title compound (329 mg, pale-yellow white crystals).. yield 62%.1H-NMR (300 MHz, CDCl3, TMS) delta: 2.06 (s, 12H), 2.13 (s, 12H), 6.70-6.73 (m, 10H), 6.81 (s, 2H), 6.90 (d, 2H, J = 8.46 Hz), 7.01 (dd, 2H, J = 7.14Hz, 7.14Hz), 7.39 (dd, 2H, J = 6.99Hz, 6.99Hz), 7.52 (dd, 2H, J = 8.49Hz, 2.28Hz), 7.84-7.88 (m, 4H).31P-NMR (121 MHz, CDCl3, 85%H3PO4) delta: -14.25 (s). (ref.: 31P-NMR (161 MHz, CDCl3, 85%H3PO4) delta: -14.9.. Journal of Organic Chemistry, vol. 59, p. 3064 (1994)

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Takeda Chemical Industries, Ltd.; EP1452537; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Analyzing the synthesis route of 391604-55-0

391604-55-0, As the paragraph descriping shows that 391604-55-0 is playing an increasingly important role.

391604-55-0, 2-(2,4-Difluorophenyl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

IrCl3 (239 mg, 0.8 mmol) was dissolved in ethylene glycol monoethyl ether / water (v / v = 3: 1, 60 ml)Further 2,4-difluoro-phenylpyridine (Hdfppy) (343.8 mg, 1.8 mmol) was added and the mixture was stirred under reflux at 135 C for 24 hours. A yellow precipitate was obtained after filtration under atmospheric pressure. The precipitate was washed with water and ether and air-dried to give a pure yellow solid (0.2 g, 41% yield).

391604-55-0, As the paragraph descriping shows that 391604-55-0 is playing an increasingly important role.

Reference£º
Patent; Nanjing University; Cao Dengke; (8 pag.)CN107353308; (2017); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI